수면 보조제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 질환별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Sleep Aids Market Summary

The global sleep aids market size was valued at USD 49.1 billion in 2025 and is projected to reach USD 95.2 billion by 2033, growing at a CAGR of 8.7% from 2026 to 2033. The increasing incidence of sleep disorders, including insomnia, sleep apnea, and restless leg syndrome, is a key factor driving the growth of the industry.

According to an article published in June 2025, under the National Center for Biotechnology Information, approximately 852 million adults globally suffer from insomnia, accounting for a global prevalence of around 16.2%, these data highlight the substantial patient population requiring diagnosis and treatment.

Insomnia remains the most common disorder, driven by factors such as anxiety, depression, and irregular sleep cycles. In addition, the growing prevalence of sleep apnea, closely linked to obesity and cardiovascular diseases, is increasing the demand for medical devices such as CPAP systems. As diagnosis rates improve and awareness increases, more patients are seeking treatment, thereby driving demand across pharmaceuticals, devices, and sleep-support products. This high disease

prevalence, combined with its association with chronic conditions such as cardiovascular diseases and mental health disorders, is driving demand for:

• Prescription sleep medications
• CPAP and sleep apnea devices
• Diagnostic and monitoring solutions

In addition, modern lifestyle patterns, characterized by high stress, long working hours, and excessive screen exposure, are significantly contributing to poor sleep quality. Rapid urbanization and digitalization have disrupted circadian rhythms, leading to delayed sleep onset and reduced sleep duration. The widespread use of smartphones and digital devices before bedtime suppresses melatonin production, further aggravating sleep disorders. Therefore, a growing number of consumers are actively seeking solutions such as sleep medications, supplements, and wearable sleep technologies. This shift toward proactive sleep management is accelerating the adoption of both clinical and consumer sleep aids, thereby supporting sustained market growth.

Global Sleep Aids Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global sleep aids market report on the basis of product, disorder, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Medications
• Sleep Therapy Devices
  • Positive Airway Pressure (PAP) Devices
  • Oral Appliances
  • Wearable Sleep Trackers
• Sleep Environment Products
• Sleep Laboratory & Diagnostic Services
• Disorder Outlook (Revenue, USD Million, 2021 - 2033)
• Insomnia
• Obstructive Sleep Apnea (OSA)
• Narcolepsy
• Parasomnias (e.g., Sleepwalking, Night Terrors)
• Restless Legs Syndrome (RLS)
• Other Sleep Disorders
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Platforms
• Drug Stores
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Disorder
  • 1.1.3. Distribution Channel
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Sleep Aids Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Sleep Aids Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Sleep Aids Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Sleep Aids Market by Product Outlook
• 4.4. Medications
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Sleep Therapy Devices
  • 4.5.1. Positive Airway Pressure (PAP) Devices
    • 4.5.1.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.5.2. Oral Appliances
    • 4.5.2.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.5.3. Wearable Sleep Trackers
    • 4.5.3.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.6. Sleep Environment Products
  • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.7. Sleep Laboratory & Diagnostic Services
  • 4.7.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Sleep Aids Market: Disorder Estimates & Trend Analysis

• 5.1. Disorder Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Sleep Aids Market by Disorder Outlook
• 5.4. Insomnia
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Obstructive Sleep Apnea (OSA)
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.6. Narcolepsy
  • 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.7. Parasomnias (e.g., Sleepwalking, Night Terrors)
  • 5.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.8. Restless Legs Syndrome (RLS)
  • 5.8.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Sleep Aids Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Sleep Aids Market by Distribution Channel Outlook
• 6.4. Hospital Pharmacies
  • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.6. E-Commerce Platforms
  • 6.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.7. Drug Stores
  • 6.7.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Sleep Aids Market: Regional Estimates & Trend Analysis, By product, By disorder, By Distribution Channel

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Key company market share/position analysis, 2025
• 8.3. Company Profiles
  • 8.3.1. Merck & Co., Inc.
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Pfizer Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Sanofi S.A.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. GSK plc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Takeda Pharmaceutical Company Limited
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Teva Pharmaceutical Industries Ltd.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Koninklijke Philips N.V.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. ResMed Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Fisher & Paykel Healthcare Corporation Limited
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Drive DeVilbiss Healthcare LLC
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Compumedics Limited
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Cadwell Industries, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Tempur World, LLC
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives